Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 115, Issue -, Pages 82-97Publisher
ELSEVIER
DOI: 10.1016/j.addr.2017.06.004
Keywords
Combination anticancer therapy; Nucleic acids; Small-molecular drugs; Nanomedicine; Drug delivery systems
Categories
Funding
- National Natural Science Foundation of China [81373342]
- PUMC Youth Fund the Fundamental Research Funds for the Central Universities [2017350003]
Ask authors/readers for more resources
Anticancer therapy has always been a vital challenge for the development of nanomedicine. Repeated single therapeutic agent may lead to undesirable and severe side effects, unbearable toxicity and multidrug resistance due to complex nature of tumor. Nanomedicine-based combination anticancer therapy can synergistically improve antitumor outcomes through multiple-target therapy, decreasing the dose of each therapeutic agent and reducing side effects. There are versatile combinational anticancer strategies such as chemotherapeutic combination, nucleic acid-based co-delivery, intrinsic sensitive and extrinsic stimulus combinational patterns. Based on these combination strategies, various nanocarriers and drug delivery systems were engineered to carry out the efficient co-delivery of combined therapeutic agents for combination anticancer therapy. This review focused on illustrating nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs for synergistically improving anticancer efficacy. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available